Abstract
PET/CT with choline is a diagnostic tool useful for imaging prostate cancer patients. The overall published papers in this field are referred to three variants of the same radiopharmaceutical: 11C-Choline, 18FMethylcholine and 18F-Ethylcholine.
As no data has been reported on the theoretical differences between these three variants of radiolabeled choline, this study aims to explore the knowledge on the physiological distribution of these three tracers, to compare data of imaging acquisition protocols and to verify the theoretical equivalence in terms of diagnostic accuracy and potential false positive cases that can occur in clinical practice.
A literature research about published papers was conducted regarding the physiological distribution, imaging acquisition protocols and diagnostic performance of 11C-choline, 18F-methylcholine and 18F-ethylcholine PET/CT.
Minimal differences of the “in vivo” bio-distribution of the variants of radiolabeled choline were registered. Several imaging acquisition protocols were utilized, considering the different half-decay of 11C and 18F and the early urinary excretion of 18F-FECH. The diagnostic accuracy resulted similar for all the tracers, despite an insignificant amount of data for 18F-FECH; however, some pitfalls were documented for all the variants, related to the intrinsic properties of choline as a non-tumour specific tracer.
Finally, our clinical experience with the two fluorinated kinds of choline has also been reported describing the “in vivo” bio-distribution with semi-quantitative measurement of Standardised Uptake Value in target organs.
The literature suggests these three variants of choline equally useful to be considered for prostate cancer imaging. A standardisation of acquisition protocols for fluorinated choline PET/CT has also been proposed.
Keywords: PET/CT, Choline, 18F-fluorometilcholine, 18F-FCH, 18F-fluoroethylcholine, 18F-FECH, 11C-choline, prostate cancer, molecular imaging.
Current Pharmaceutical Design
Title:Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Volume: 21 Issue: 32
Author(s): Ferdinando Calabria, Gianpasquale Gallo, Orazio Schillaci and Giuseppe Lucio Cascini
Affiliation:
Keywords: PET/CT, Choline, 18F-fluorometilcholine, 18F-FCH, 18F-fluoroethylcholine, 18F-FECH, 11C-choline, prostate cancer, molecular imaging.
Abstract: PET/CT with choline is a diagnostic tool useful for imaging prostate cancer patients. The overall published papers in this field are referred to three variants of the same radiopharmaceutical: 11C-Choline, 18FMethylcholine and 18F-Ethylcholine.
As no data has been reported on the theoretical differences between these three variants of radiolabeled choline, this study aims to explore the knowledge on the physiological distribution of these three tracers, to compare data of imaging acquisition protocols and to verify the theoretical equivalence in terms of diagnostic accuracy and potential false positive cases that can occur in clinical practice.
A literature research about published papers was conducted regarding the physiological distribution, imaging acquisition protocols and diagnostic performance of 11C-choline, 18F-methylcholine and 18F-ethylcholine PET/CT.
Minimal differences of the “in vivo” bio-distribution of the variants of radiolabeled choline were registered. Several imaging acquisition protocols were utilized, considering the different half-decay of 11C and 18F and the early urinary excretion of 18F-FECH. The diagnostic accuracy resulted similar for all the tracers, despite an insignificant amount of data for 18F-FECH; however, some pitfalls were documented for all the variants, related to the intrinsic properties of choline as a non-tumour specific tracer.
Finally, our clinical experience with the two fluorinated kinds of choline has also been reported describing the “in vivo” bio-distribution with semi-quantitative measurement of Standardised Uptake Value in target organs.
The literature suggests these three variants of choline equally useful to be considered for prostate cancer imaging. A standardisation of acquisition protocols for fluorinated choline PET/CT has also been proposed.
Export Options
About this article
Cite this article as:
Calabria Ferdinando, Gallo Gianpasquale, Schillaci Orazio and Cascini Lucio Giuseppe, Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150818110422
DOI https://dx.doi.org/10.2174/1381612821666150818110422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolution of Peptide-Based Prostate-Specific Membrane Antigen (PSMA) Inhibitors: An Approach to Novel Prostate Cancer Therapeutics
Current Medicinal Chemistry Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Nanotechnology: A Successful Approach to Improve Oral Bioavailability of Phytochemicals
Recent Patents on Drug Delivery & Formulation The IGF-I Axis in Thyroid Carcinoma
Current Pharmaceutical Design From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Anti-cancer Scopes and Associated Mechanisms of Scutellaria Extract and Flavonoid Wogonin
Current Cancer Therapy Reviews IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets <i>Fernandoa Adenophylla</i>: A review of its Phytochemistry, Traditional and Pharmacology use and Future Aspects
Current Traditional Medicine Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Anti-resorptive Drugs and their Impact on Maxillofacial Bone among Cancer Patients
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs: Association with Radioresistant and Potential Uses of Natural Remedies as Green Gene Therapeutic Approaches
Current Gene Therapy